IceCure Medical Achieves 83% Growth in U.S. Sales and Expands Commercial Reach Across 21 States

IceCure Medical: A Year of Impressive Growth



IceCure Medical Ltd., which trades on NASDAQ under the ticker ICCM, has recently published its latest financial and operational results for the nine months ending September 30, 2026. This period marked a significant milestone for the company, showcasing tremendous growth in the U.S. market, particularly with an impressive 83% year-over-year surge in U.S. sales and an expansion of their commercial presence from 11 to 21 states.

Financial Highlights



In the first nine months of 2026, IceCure reported total revenues of approximately $2.6 million, compared to around $2.1 million during the same period in 2025, reflecting a robust 26% increase in revenue. The company’s flagship product, ProSense®, along with its cryoprobes, contributed significantly to this growth as sales doubled year over year. Gross profit for this period also saw an uptick, reaching $762,000, a 22% increase over the previous year’s $626,000. However, it is important to note that IceCure incurred an operating loss of $12.9 million, which was higher than the $10.8 million operating loss reported in the same period of the prior year.

Clinical Advancements



Beyond financials, IceCure has made notable strides in its clinical research initiatives. The ChoICE Study, which evaluates the effectiveness of ProSense® cryoablation treatment for low-risk breast cancer, gained momentum as they launched their first clinical sites at the West Cancer Center in Germantown, TN, and Adventist Health Glendale in Glendale, CA. After obtaining Institutional Review Board (IRB) approvals, this study aims to lay the groundwork for a broader acceptance of their innovative cryoablation technology.

Additionally, since the end of the third quarter, IceCure announced the successful enrollment of the first two patients in the ChoICE Study, marking a significant step in the company’s clinical development efforts. The first treatment was conducted at West Cancer Center under the guidance of Dr. Richard E. Fine.

Regulatory Achievements



In terms of international expansion, IceCure celebrated a notable victory by securing regulatory approval from China’s National Medical Products Administration to market ProSense® as a Class III medical device. Furthermore, they have entered an exclusive distribution agreement for ProSense® systems in the Netherlands, underlining IceCure’s commitment to extending its global footprint.

Expanding Commercial Operations



With an eye toward further growth, IceCure has bolstered its U.S. commercial team by adding several experienced professionals in key markets like New York, Southern California, and the Midwest, among others. Their relentless efforts in marketing and sales, coupled with the participation in crucial medical events such as Aptitude Health's TME Take the Lead in Breast Cancer Fall Summit and the EUSOBI Congress, demonstrate the company's drive to engage with leading medical practitioners within the field.

Looking Ahead



IceCure Medical’s trajectory shows promise as the clinical evidence supporting cryoablation continues to strengthen, highlighted by recent peer-reviewed publications emphasizing its role in the treatment of breast cancer cases. Furthermore, the Society of Interventional Oncology's petition to include cryoablation as a treatment option in breast cancer guidelines may broaden treatment availability and adoption.

In sum, IceCure is not just posting impressive financial results but is also setting a solid foundation for future growth in the healthcare industry. As the company continues to innovate in minimally invasive solutions for cancer treatments, stakeholders are optimistic about the sustainable direction of IceCure Medical.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.